REG - GSK PLC - GSK RSV vaccine for older adults approved in Japan

GSKAnnouncement

25/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230925:nRSY5030Na&default-theme=true

RNS Number : 5030N  GSK PLC  25 September 2023

Issued: 25 September 2023, London UK

 

Japan's Ministry of Health, Labour and Welfare approves GSK's Arexvy, the
country's first respiratory syncytial virus (RSV) vaccine for older adults

 

·   Arexvy's approval will help protect adults 60 years of age and older in
Japan from RSV disease for the first time, including those living with
underlying medical conditions who are most at risk of severe RSV disease

·   RSV causes an estimated 63,000 hospitalisations and 4,500 in-hospital
deaths in adults 60 years of age and older in Japan each year

·   The approval - the first in Asia - is based on a comprehensive phase
III programme, which enrolled over 1,000 Japanese participants

 

GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health,
Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus
vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory
syncytial virus) disease for adults 60 years of age and above. This is the
first time an RSV vaccine for older adults has been approved in Japan.

 

Tony Wood, Chief Scientific Officer at GSK, said: "Arexvy is Japan's first
approved RSV older adult vaccine, and is a major advance for public health
with the potential to help protect around 43.5 million Japanese people aged 60
and older 1 . Following key approvals in the US, EU, UK and Canada earlier
this year, today's authorisation reinforces GSK's industry-leading vaccine
portfolio".

 

RSV is a common, contagious respiratory virus 2  that causes an estimated
470,000 hospitalisations and 33,000 deaths each year in adults 60 years of age
and older in industrialised countries, including approximately 63,000
hospitalisations and 4,500 deaths in Japan. 3  Its impact on healthcare
systems may further increase as the population ages. Those with underlying
medical conditions, such as chronic heart disease, chronic lung disease or
diabetes, account for the majority of RSV hospitalisations. 4 

 

The approval has been granted based on data from the pivotal AReSVi-006 (Adult
Respiratory Syncytial Virus) phase III vaccine efficacy trial, published in
the New England Journal of Medicine
(https://www.nejm.org/doi/full/10.1056/NEJMoa2209604
(https://www.nejm.org/doi/full/10.1056/NEJMoa2209604) ). In the trial, the
vaccine showed statistically significant and clinically meaningful overall
efficacy of 82.6% (96.95% CI, 57.9-94.1, 7 of 12,466 in the Arexvy arm vs 40
of 12,494 in the placebo arm) against RSV-LRTD in adults aged 60 years and
older, meeting the primary endpoint. In addition, secondary descriptive
endpoints show that efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 in the
Arexvy arm vs 18 of 4,861 in the placebo arm) in older adults with at least
one underlying medical condition of interest, such as certain
cardiorespiratory and endocrine-metabolic conditions. 5 

 

The vaccine was generally well tolerated. The most frequently observed
solicited adverse events were injection site pain, fatigue, myalgia, headache
and arthralgia. These were generally mild to moderate and transient.

 

This is the fifth major regulatory approval for Arexvy, building on approvals
from the US Food and Drug Administration
(https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/),
the European Commission
(https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/),
and the regulatory authorities in the UK and Canada.

 

About Arexvy

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant
glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This
antigen is combined with GSK's proprietary AS01(E) adjuvant.

 

The MHLW has approved Arexvy for the prevention of RSV (respiratory syncytial
virus) disease for adults aged 60 years and above. The use of this vaccine
should be in accordance with official recommendations. As with any vaccine, a
protective immune response may not be elicited in all vaccinees.

 

Arexvy, the trade name approved in the US, EU/EEA, UK, Canada and Japan,
remains subject to regulatory approval in other markets.

 

The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant
licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc.
STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus.

 

About AReSVi-006

This is a randomised, placebo-controlled, observer-blind, multi-country phase
III trial to demonstrate the efficacy of a single dose of GSK's adjuvanted
RSVPreF3 vaccine in adults aged 60 years and above. Approximately 25,000
participants were enrolled from 17 countries. Initial results were published
in the New England Journal of Medicine in February 2023.

About respiratory syncytial virus (RSV) in adults

 

RSV is a common contagious virus affecting the lungs and breathing passages.
Older adults are at high risk for severe disease. RSV can exacerbate
conditions, including chronic obstructive pulmonary disease (COPD), asthma and
chronic heart failure and can lead to severe outcomes, such as pneumonia,
hospitalisation, and death. Each year, RSV causes over 470,000
hospitalisations and 33,000 in-hospital deaths in adults 60 years of age and
older in industrialised countries, including approximately 63,000
hospitalisations and 4,500 deaths in Japan. Adults with underlying conditions
are more likely to seek medical advice and have higher hospitalisation rates
than adults without these conditions.

 

Please refer to the updated Product Information (PI) for important dosage,
administration, and safety information in Japan which will shortly be updated
at this link: https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html
(https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html)

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q2 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

References

 1  Statistics Bureau Home Page/Population Estimates Monthly Report
(https://www.stat.go.jp/english/data/jinsui/tsuki/index.html)

 2  Centers for Disease Control and Prevention. RSV in Older Adults and Adults
with Chronic Medical Conditions. Accessed March 2023. Available at:
cdc.gov/rsv/high-risk/older-adults.html
(http://www.cdc.gov/rsv/high-risk/older-adults.html)

 3  Savic M et al., "Respiratory syncytial virus disease burden in adults aged
60 years and older in high-income countries: A systematic literature review
and meta-analysis", in Influenza Other Respir Viruses 2023;17(1):e13031.
doi.org/10.1111/irv.13031

 4  Tseng HF, Sy LS, Ackerson B, et al., "Severe morbidity and short- and mid-
to long-term mortality in older adults hospitalized with respiratory syncytial
virus infection" in J Infect Dis. 2020;222(8):1298-1310.
doi:10.1093/infdis/jiaa361

 5  The New England Journal of Medicine, Respiratory Syncytial Virus Prefusion
F Protein Vaccine in Older Adults
https://www.nejm.org/doi/10.1056/NEJMoa2209604
(https://www.nejm.org/doi/10.1056/NEJMoa2209604)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGZLKKVGFZG